Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: A drive module assembly includes a housing defining a housing interior for containing a lubricant. The housing interior is further defined as a first housing interior and a second housing interior. The drive module assembly also includes a first input shaft configured to receive rotational torque from a first power source, a first gear train rotatably coupled to the first input shaft, a first output shaft rotatably coupled to the first gear train, a second input shaft configured to receive rotational torque from a second power source, a second gear train disposed rotatably coupled to the second input shaft, and a second output shaft rotatably coupled to the second gear train. The first housing interior and the second housing interior are fluidly separate from one another.

Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: A drive module assembly includes a housing defining a housing interior for containing a lubricant. The housing interior is further defined as a first housing interior and a second housing interior. The drive module assembly also includes a first input shaft configured to receive rotational torque from a first power source, a first gear train rotatably coupled to the first input shaft, a first output shaft rotatably coupled to the first gear train, a second input shaft configured to receive rotational torque from a second power source, a second gear train disposed rotatably coupled to the second input shaft, and a second output shaft rotatably coupled to the second gear train. The first housing interior and the second housing interior are fluidly separate from one another.

Abstract: In an embodiment, a battery connector includes: power terminals configured to be coupled to a load having an input capacitance; power pins electrically coupled to the power terminals; a charge pin, the charge pin being longer than each of the power pins; and an antispark circuit electrically interposed between the charge pin and the power terminals, the antispark circuit including: a dissipation circuit configured to charge the input capacitance of the load in response to a battery being coupled to the charge pin; and a delay circuit configured to delay charging of the input capacitance of the load for a predetermined duration after the battery is coupled to the charge pin.

Abstract: A facility for constructing a display module in connection with a web page is described. The facility obtains content associated with the web page and uses the obtained content to generate a query used to select an image. The facility then generates the display module that incorporates the selected image.

Abstract: In an embodiment, a battery connector includes: power terminals configured to be coupled to a load having an input capacitance; power pins electrically coupled to the power terminals; a charge pin, the charge pin being longer than each of the power pins; and an antispark circuit electrically interposed between the charge pin and the power terminals, the antispark circuit including: a dissipation circuit configured to charge the input capacitance of the load in response to a battery being coupled to the charge pin; and a delay circuit configured to delay charging of the input capacitance of the load for a predetermined duration after the battery is coupled to the charge pin.

Abstract: In an embodiment, a battery connector includes: power terminals configured to be coupled to a load having an input capacitance; power pins electrically coupled to the power terminals; a charge pin, the charge pin being longer than each of the power pins; and an antispark circuit electrically interposed between the charge pin and the power terminals, the antispark circuit including: a dissipation circuit configured to charge the input capacitance of the load in response to a battery being coupled to the charge pin; and a delay circuit configured to delay charging of the input capacitance of the load for a predetermined duration after the battery is coupled to the charge pin.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Modular shelter systems are described herein. In one aspect, the modular shelter system includes an endcap positioned at a first end of the modular shelter system. The endcap includes a first support arch; and an endcap frame. The modular shelter system also includes a second support arch positioned at a second end of the modular shelter system. The modular shelter system also includes at least one section assembly disposed between the first support arch and the second support arch. The section assembly includes a plurality of purlins oriented along a longitudinal axis of the modular shelter system.

Abstract: Methods and systems for facilitating generation of electronic advertising messages based on model web pages. A visual content request is received that identifies a model web page. Source code is retrieved that includes patterns that can be matched to identify visual features of the model web page. Visual content information is provided to an advertising message generation service to construct advertising messages that include at least a portion of the identified visual features. Constructed advertising messages are received, including at least one modified advertising message that incorporates a user-selected image extracted from the model web page. The identified visual features of the model web page can include text format, text color, background color, images, and video sequences.

Abstract: A facility for constructing an advertising message in connection with a web page is described. The facility obtains text associated with the web page, and uses the obtained text to generate a query. The facility uses the generated query to select a stock photography image, and generates an advertising message that incorporates the selected stock photography image.

Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.

Abstract: A landing gear system includes an axle having an internal cavity and a wheel rotatably coupled to the axle. A drive shaft is mounted within the cavity to be rotatable about an axis. The landing gear system further includes a rod slidably mounted within the drive shaft and a clutch. The clutch has a first portion that is coupled to the rod and rotates with the drive shaft. A second portion of the clutch is fixedly coupled to the wheel. The rod selectively reciprocates along the axis between a first position and a second position to engage and disengage the clutch.